Market Overview

UPDATE: Jefferies Raises PT to $41 on Bristol-Myers Squibb on Long-Term Growth Prospects

Share:
Related BMY
U.S. Food and Drug Administration Accepts for Priority Review the Biologics License Application for Empliciti (elotuzumab) for the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies
Benzinga's M&A Chatter for Thursday August 27, 2015
Premarket Biotech Digest: Natural Killer Cells, Lipocine NDA, FDA Calendar (Seeking Alpha)

Jefferies maintained Bristol-Myers Squibb (NYSE: BMY) with a Buy rating and raisd the price target from $39.00 to $41.00.

Jefferies said, "2013 will likely deliver several major catalysts that will shape the direction of Bristol-Myers' mid to long term growth. We believe that Eliquis will beat launch expectations providing meaningful earnings momentum, whilst several major R&D catalysts (anti-PD1 and Yervoy) further expand the PE multiple. We reiterate our Buy rating and have increased our PT to $41 (from $39)."

Bristol-Myers Squibb closed at $36.93 on Monday.

Latest Ratings for BMY

DateFirmActionFromTo
Aug 2015JefferiesMaintainsHold
Aug 2015Piper JaffrayUpgradesUnderN
Aug 2015JefferiesMaintainsHold

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (BMY)

View Comments and Join the Discussion!

Get Benzinga's Newsletters